First-of-its-Kind cancer drug targets 'Guardian Gene' mutation
Disease control
Recruiting now
This is a first-in-human study testing a new drug called CLSP-1025 for adults with advanced solid tumors that have a specific genetic change called the p53 R175H mutation. The main goals are to find a safe dose and see if the drug can help control the cancer. The drug works by en…
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC